Actinium Pharmaceuticals (ATNM) AI Stock Analysis

• Market Cap: $49.29M
• Dividend Yield: N/A
• Average Volume (3M): 169.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: -100.00%
• EPS Growth: 13.14%
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 31,195,890
• 10 Day Avg. Volume: 154,271
• 30 Day Avg. Volume: 169,719
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.65
• Enterprise Value/Revenue: -39.54
• Enterprise Value/Gross Profit: 155.46
• Enterprise Value/Ebitda: 0.73
• 1Y Price Target: $6.00
• Price Target Upside: 275.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: ―

Actinium Pharmaceuticals faces substantial financial challenges due to declining revenues, net losses, and negative cash flows, contributing to a low overall score. The technical analysis suggests a bearish trend, with the stock trading below key moving averages and negative MACD. The valuation is further weakened by a negative P/E ratio and absence of dividends. These factors significantly impact the stock's attractiveness, resulting in a score towards the lower end of the scale.

Positive Factors

Clinical Program

The clinical program for trials of Actimab-A in combination with Keytruda or Opdivo represents a significant event for the company, marking its first entry into solid tumors in the clinic.

Financial Stability

The current cash runway now extends into 2028, indicating strong financial stability.

Regulatory Progress

Actinium has reached an agreement with the FDA on the finalized protocol for the Phase 2/3 trial of Iomab-B, showing regulatory progress.

Negative Factors

Competitor Performance

ATNM-400, a non-PSMA targeted Ac-225 radiotherapy, showed superior prostate cancer cell killing to Xtandi, overcame Xtandi resistance, and outperformed Pluvicto in vitro and in vivo, including resistant models.

Trial Challenges

Checkpoint inhibitors have transformed the treatment landscape for advanced cancers, yet efficacy can be limited due to resistance mechanisms, and Actimab-A targets CD33 to overcome these resistance mechanisms.

Actinium Pharmaceuticals Business Overview & Revenue Model

Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

How the Company Makes Money

Actinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceutical companies to co-develop and commercialize its proprietary therapies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Actinium's focus on advancing its pipeline through clinical trials also positions it to earn revenue from the eventual approval and sale of its therapeutic products. Additionally, the company may engage in research and development agreements with academic and research institutions to further its scientific initiatives.

Actinium Pharmaceuticals Financial Statement Overview

Summary

Actinium Pharmaceuticals faces significant financial challenges with declining revenues, substantial net losses, and negative cash flows. While the balance sheet shows low leverage, the company's ability to generate revenue and positive cash flows remains a key concern. Continued reliance on external financing poses risks if not managed carefully.

Income Statement

Actinium Pharmaceuticals shows a negative revenue growth trajectory with declining revenues over the years, zero revenue in the latest report, and consistent net losses. Profitability metrics, such as net profit margin, are negative due to significant operating losses and no gross profit, indicating high operational costs relative to revenue.

Balance Sheet

The company has a low debt-to-equity ratio, suggesting a low reliance on debt financing, which is positive. However, the persistent negative net income affects the return on equity (ROE), making it negative. The equity ratio is relatively stable, indicating a moderate level of equity funding compared to total assets.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash outflows from operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. Despite this, there is a significant reliance on financing activities to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	810.00K	0.00	81.00K	1.03M	1.14M	0.00
Gross Profit	-206.00K	-811.00K	81.00K	1.03M	1.14M	-447.00K
EBITDA	-43.84M	-37.43M	-51.13M	-33.41M	-24.44M	-21.77M
Net Income	-41.04M	-38.24M	-48.82M	-33.02M	-24.77M	-22.21M
Balance Sheet
Total Assets	63.02M	76.90M	81.44M	114.19M	80.39M	66.40M
Cash, Cash Equivalents and Short-Term Investments	59.93M	72.90M	76.68M	108.91M	77.83M	63.56M
Total Debt	1.29M	1.57M	2.11M	2.58M	310.00K	738.00K
Total Liabilities	44.00M	44.14M	45.07M	47.71M	6.84M	5.08M
Stockholders Equity	19.01M	32.76M	36.38M	66.48M	73.55M	61.32M
Cash Flow
Free Cash Flow	-30.69M	-33.08M	-47.49M	8.28M	-21.00M	-21.87M
Operating Cash Flow	-30.69M	-33.07M	-47.34M	8.64M	-20.87M	-21.62M
Investing Cash Flow	0.00	-11.00K	-153.00K	-366.00K	-133.00K	-253.00K
Financing Cash Flow	4.59M	29.32M	14.87M	23.11M	35.22M	76.18M

Actinium Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.6 is below the 20-day moving average (MA) of 1.68, below the 50-day MA of 1.62, and above the 200-day MA of 1.43, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 43.75 is Neutral, neither overbought nor oversold. The STOCH value of 23.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.

Actinium Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
IFRX	46 Neutral	$110.77M	―	-62.38%	―	178.84%	-40.60%
GANX	46 Neutral	$63.27M	―	-240.21%	―	―	49.82%
ATNM	41 Neutral	$49.29M	―	-130.59%	―	-100.00%	13.14%
UNCY	28 Underperform	$77.01M	―	-3987.11%	―	―	68.02%
ANL	―	$64.58M	―		―	―	―
JUNS	―	$42.84M	―		―	―	―

Actinium Pharmaceuticals Corporate Events

Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes

Actinium Pharmaceuticals, Inc. held its 2024 annual stockholder meeting where Sandesh Seth and Jeffrey W. Chell were re-elected as Class II directors to serve until 2027. Additionally, Marcum LLP was ratified as the independent public accountant for the fiscal year 2024. The meeting saw the participation of 19,724,287 shares, with all proposals receiving approval from stockholders.

Actinium Pharmaceuticals Strengthens Board with New Appointment

Actinium Pharmaceuticals has appointed Dr. June Almenoff, a seasoned biopharma executive with over 25 years of experience in drug development and leadership, to its Board of Directors. Dr. Almenoff’s extensive background in translational medicine and business development, including leading successful product approvals, is expected to bolster Actinium’s strategic vision and innovation in targeted radiotherapies. Her expertise will be invaluable as Actinium aims to enhance its position in the radiopharmaceutical sector, focusing on innovative treatments for oncology patients.